Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q3 FY20 Earnings Presentation
11 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Feb 4, 2020
Slide 1: J. B. Chemicals & Pharmaceuticals Limited
J. B. CHEMICALS & PHARMACEUTICALS LIMITED February 4, 2020 National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block-G, Bandra Kurla Complex Bandra (E) Mumbai 400 051 Scrip Code : JBCHEPHARM Dear Sir, Sub : Presentation Enclosed is investor presentation on consolidated performance during quar
Slide 2: Q3 - FY20
Q3 -FY20
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Company Overview
Company Overview • J.B Chemicals and Pharmaceuticals Ltd. (JBCPL) was incorporated in 1976 under the chairmanship of Mr. J.B Mody. • Over the past four decades JBCPL has established brands not only in India but also internationally to 30+ countries, supplying affordable and quality products. • JBCPL
Slide 5: Performance Highlights
Performance Highlights Consolidated Q3 FY 19 Q3 FY 20 YTD Dec 19 YTD Dec 20 Q3 FY 19 Q3 FY 20 YTD Dec 19 YTD Dec 20 Q3 FY 19 Q3 FY 20 YTD Dec 19 YTD Dec 20 4
Slide 6: Q3-2019-20 Consolidated Financial Performance
Q3-2019-20 Consolidated Financial Performance (Rs. in crores) Particulars Q3 YTD December, 2019 2019-20 2018-19 YoY 2019-20 2018-19 YoY Growth (%) Growth (%) Sales 420.04 372.86 14.16 1303.66 1198.22 16.04 Other Operating income 8.59 9.17 (6.32) 27.50 26.06 5.53 Other Income 16.38 15.82 3.54 47.50 2
Slide 7: Q3-2019-20 Consolidated Sales Performance
Q3-2019-20 Consolidated Sales Performance (Rs. in crores) Sales Q3 YTD December, 2019 2019-20 2018-19 YoY 2019-20 2018-19 YoY Growth Growth (%) (%) Domestic Formulations 183.97 161.15 14.16 595.00 512.73 16.04 Formulations exports 139.76 133.07 5.02 449.39 442.76 1.50 API Business 17.78 19.49 (8.77)
Slide 8: Performance Highlights
Performance Highlights (Rs. in crores) Sales Q3 2019-20 Sales Q3 2018-19 Growth (%) Domestic Formulations 168.66 148.29 13.74 Domestic Contrast Media 15.30 12.85 19.07 Russia-CIS 39.26 38.08 3.10 Global Business (RoW) 156.07 138.37 12.79 Other formulations exports 16.00 11.53 38.76 API Sales 17.78 1
Slide 9: Performance Highlights
Performance Highlights • EBIDTA of Rs. 89.60 crores was 21.33% of sales, up from 20.91% in the same quarter in previous year, due to cost optimization. • Sales of Russian subsidiary (included in Russia-CIS above) was Rs. 26.55 crores, increase of 48% over the same quarter previous year. • Sales of S
Slide 10: Quarterly - Consolidated Income Statement
Quarterly - Consolidated Income Statement (Rs. in Lakhs) Actual % to Actual % to Growth PART ICULARS 2019-20 Sales 2018-19 Sales % Net Sales 42,004.2 100.0 37,285.7 100.0 12.7% Operating Income 859.1 2.0 916.9 2.5 -6.3% Total Income 42,863.3 102.0 38,202.6 102.5 12.2% Cost Of Materials 15,034.8 35.8
Slide 11: YTD - Consolidated Income Statement
YTD - Consolidated Income Statement (Rs. in Lakhs) Actual % to Actual % to Growth PAR T ICULAR S 2019-20 Sales 2018-19 Sales % Net Sales 1,30,366.3 100.0 1,19,822.6 100.0 8.8% Operating Income 2,749.7 2.1 2,605.9 2.2 5.5% Total Income 1,33,116.0 102.1 1,22,428.5 102.2 8.7% Cost Of Materials 48,380.2
J. B. Chemicals & Pharmaceuticals — Q3 FY20 Earnings Presentation on 6ix